The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

Dec. 02, 2019
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Yan Chen, Lexington, MA (US);

Steven M. Shamah, Acton, MA (US);

Csaba Pazmany, Belmont, MA (US);

Jui Dutta-Simmons, Lexington, MA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01);
Abstract

Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.


Find Patent Forward Citations

Loading…